← Eichor
Study identifier: NCT07672561 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Condition: Moderate to Severe Plaque Psoriasis  ·  Sponsor: Zhejiang Wenda Pharma Technology LTD.

PhasePhase 3
Planned participants375
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersYes

About this study

The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.

This description comes directly from the study's public registry record.

Talk to the study team

Lu Qianjin  ·  +8613787097676  ·  qianlu5860@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital of Dermatology, Chinese Academy of Medical SciencesNanjing, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07672561